Comparing Galectin Therapeutics (GALT) & The Competition

Galectin Therapeutics (NASDAQ: GALT) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Galectin Therapeutics to similar companies based on the strength of its profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings & Valuation

This table compares Galectin Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Galectin Therapeutics N/A -$21.43 million -9.82
Galectin Therapeutics Competitors $217.40 million -$39.40 million -63.10

Galectin Therapeutics’ peers have higher revenue, but lower earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Galectin Therapeutics and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galectin Therapeutics 0 1 3 0 2.75
Galectin Therapeutics Competitors 572 2506 6735 133 2.65

Galectin Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 13.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.00%. Given Galectin Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than its peers.

Institutional and Insider Ownership

10.8% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 38.8% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


This table compares Galectin Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galectin Therapeutics N/A -1,747.01% -160.00%
Galectin Therapeutics Competitors -4,594.03% -35.12% -43.24%

Risk & Volatility

Galectin Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, Galectin Therapeutics’ peers have a beta of 1.48, meaning that their average share price is 48% more volatile than the S&P 500.


Galectin Therapeutics beats its peers on 8 of the 13 factors compared.

About Galectin Therapeutics

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply